Pettijohn Erin M, Ma Shuo
Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 N. St Clair, Suite 850, Chicago, IL, 60611, USA.
Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 303 E Superior St, Lurie 3-103, Chicago, IL, 60611, USA.
Curr Hematol Malig Rep. 2017 Feb;12(1):20-28. doi: 10.1007/s11899-017-0358-1.
The standard of care for the treatment of chronic lymphocytic leukemia (CLL) has traditionally been chemoimmunotherapy. For patients who are unable to tolerate chemotherapy and those with high risk 17p deletions, there were previously few feasible or efficacious treatment options. Novel targeted agents for the treatment of CLL have the potential to offer long-term, durable remissions and offer promising treatment options for those in previously challenging population groups. Current targeted agents in CLL are directed against B cell receptor-associated tyrosine kinases such as BTK and SYK, the downstream PI3-kinase pathway, as well as the antiapoptotic protein BCL-2. The optimal sequencing of these agents has yet to be determined, although the side effect profile differs significantly and may dictate choice of therapy until further randomized data becomes available.
慢性淋巴细胞白血病（CLL）的传统治疗标准一直是化疗免疫疗法。对于无法耐受化疗的患者以及有高危17p缺失的患者，以前几乎没有可行或有效的治疗选择。用于治疗CLL的新型靶向药物有可能实现长期、持久的缓解，并为那些以前面临挑战的人群提供有前景的治疗选择。目前用于CLL的靶向药物针对B细胞受体相关酪氨酸激酶，如BTK和SYK、下游的PI3激酶途径以及抗凋亡蛋白BCL-2。尽管这些药物的副作用显著不同，并且在获得更多随机数据之前可能决定治疗选择，但这些药物的最佳用药顺序尚未确定。
